Staging of Acute Kidney Injury
AKI is staged using the KDIGO criteria into three stages based on serum creatinine changes and/or urine output, with Stage 1 representing the mildest injury and Stage 3 the most severe, including any patient requiring renal replacement therapy. 1
KDIGO Staging System
The current standard for AKI staging uses the following criteria 1:
Stage 1
- Serum creatinine: 1.5-1.9 times baseline OR ≥0.3 mg/dL (26.5 μmol/L) increase
- Urine output: <0.5 mL/kg/h for 6-12 hours
Stage 2
- Serum creatinine: 2.0-2.9 times baseline
- Urine output: <0.5 mL/kg/h for ≥12 hours
Stage 3
- Serum creatinine: ≥3.0 times baseline OR increase to ≥4.0 mg/dL (353.6 μmol/L) OR initiation of renal replacement therapy
- Urine output: <0.3 mL/kg/h for ≥24 hours OR anuria for ≥12 hours
- Special consideration: In patients <18 years, decrease in eGFR to <35 mL/min/1.73 m² also qualifies as Stage 3
Critical Diagnostic Timeframes
The diagnosis requires meeting criteria within specific windows 1:
- 0.3 mg/dL increase: Must occur within 48 hours
- 1.5-fold increase: Must be known or presumed to have occurred within 7 days
Patients are staged based on the highest severity criterion met, whether by creatinine or urine output. Staging occurs over the entire course of AKI, not just at initial presentation 1.
Important Clinical Nuances
Urine Output Limitations
While included in staging criteria, urine output has significant limitations in clinical practice 2, 3:
- Less reliable than serum creatinine for diagnosis
- Particularly problematic in cirrhotic patients with ascites who may be oliguric despite normal GFR
- Influenced by diuretic therapy, making collection often inaccurate
- Kinetic changes in serum creatinine remain the primary diagnostic tool 3
Stage 1 Heterogeneity
Stage 1 AKI represents a heterogeneous population because only one criterion needs to be met 1. A 0.3 mg/dL increase may represent a much smaller percentage change than a 50% increase, depending on baseline creatinine. Recent evidence suggests Stage 1 may benefit from subdivision 4:
- Stage 1a: 0.3 mg/dL absolute increase (odds ratio for mortality: 4.3)
- Stage 1b: 50% relative increase (odds ratio for mortality: 10.9)
These substages show clinically meaningful differences in length of stay and mortality 4.
Stage 3 Considerations
The KDIGO modification for Stage 3 creates a potential issue: any creatinine ≥4.0 mg/dL with an acute increase of ≥0.3 mg/dL qualifies as Stage 3 1. This means a patient with CKD and creatinine rising from 4.0 to 4.3 mg/dL (only 7.5% increase) receives the same classification as someone with normal baseline whose creatinine triples. This has not been validated in CKD populations and may overclassify severity 1.
Special Population: Cirrhosis
In cirrhotic patients, the 1.5 mg/dL threshold retains prognostic significance 3, 5:
- Stage 1 can be subdivided: Stage 1-A (peak sCr <1.5 mg/dL) has mortality similar to no AKI
- Stage 1-B (peak sCr ≥1.5 mg/dL) shows significantly higher mortality
- Progression through stages strongly correlates with mortality 3
Common Pitfalls
Missing AKI due to volume expansion: Aggressive fluid resuscitation may dilute creatinine, masking true GFR decline 6
Baseline creatinine uncertainty: The definition assumes baseline is "known or presumed" within 7 days, but this is often unavailable 1
Creatinine limitations in cirrhosis: Decreased muscle mass, increased tubular secretion, volume overload, and bilirubin interference all affect creatinine accuracy 3, 5
Overreliance on urine output: This criterion is physiologically variable and influenced by multiple non-renal factors 2, 3
Post-AKI Follow-up
Evaluate all patients 3 months after AKI for resolution, new-onset CKD, or worsening of pre-existing CKD 1. Even patients who recover from AKI remain at increased risk for future CKD and should be monitored accordingly.